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A B S T R A C T
The development of diagnostic tests which can readily differentiate between vaccinated and 
tuberculosis-infected individuals is crucial for the wider utilization of bacillus Calmette-Guérin 
(BCG) as vaccine in humans and animals. BCG_0092 is an antigen that elicits specific delayed 
type hypersensitivity reactions similar in size and morphological aspects to that elicited by 
purified protein derivative, in both animals and humans infected with the tubercle bacilli. We 
carried out bioinformatics analyses of the BCG_0092 and designed a diagnostic test by using 
the predicted MHC class I epitopes. In addition, we performed a knockout of this gene by 
homologous recombination in the BCG vaccine strain to allow differentiation of vaccinated 
from infected individuals. For that, the flanking sequences of the target gene (BCG_0092)
were cloned into a suicide vector. Spontaneous double crossovers, which result in wild type 
revertants or knockouts were selected using SacB. BCG_0092 is present only in members of 
the Mycobacterium tuberculosis complex. Eight predicted MHC class I epitopes with potential for 
immunological diagnosis were defined, allowing the design of a specific diagnostic test. The 
strategy used to delete the (BCG_0092) gene from BCG was successful. The knockout genotype 
was confirmed by PCR and by Southern blot. The mutant BCG strain has the potential of 
inducing protection against tuberculosis without interfering with the diagnostic test based on 
the use of selected epitopes from BCG_0092. 
human tuberculosis.2,3 However, a major constraint in the 
use of attenuated mycobacterial vaccines such as BCG is that 
vaccination interferes in the TB diagnosis.
The acid fast bacilli smear microscopy and culture on 
Löwenstein-Jensen medium are still the “gold standards” 
for the diagnosis of active TB.4 However, the detection of 
extrapulmonary TB is often more difficult. An alternative 
Introduction
Tuberculosis (TB) in humans and animals continues to cause 
major health problems on a global scale.1 An important 
control strategy for the prevention of this disease is the use of 
effective vaccines. The Mycobacterium bovis bacillus Calmette-
Guérin (BCG) vaccine has been widely used for controlling 
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for rapid and cost-effective diagnostic methods for TB is 
molecular diagnosis using PCR5,6 and immunodiagnosis, which 
uses the specific humoral and cellular immune responses of 
the host to infer the presence of infection or disease.7,8 The 
tuberculin skin test (Mantoux) is a diagnostic test that has 
been used for more than 85 years.9 However, the test lacks 
specificity for M. tuberculosis/bovis due to the following factors: 
1) exposure to or infection with mycobacteria other than 
M. tuberculosis/bovis; 2) vaccination with BCG; and 3) presence 
in the purified protein derivative (PPD) of several antigens 
shared by Mycobacterium spp.10 Tests based on PPD cannot 
distinguish between tuberculosis infection, M. bovis BCG 
vaccination or exposure to environmental mycobacteria.
More specific and sensitive alternatives to skin testing 
have been investigated. Detection of gamma-interferon (IFNγ) 
by sandwich ELISA has been tested.11 Recombinant proteins 
MPB59, MPB64, MPB70 and ESAT 6 have all been tested in 
differential diagnostic tests based on IFNγ detection.12,13
A recombinant M. tuberculosis protein present in PPD 
that elicits strong and tuberculosis specific delayed type 
hypersensitivity (DTH) in guinea pigs has been identified 
and characterized.14 The DPPD (corresponding to BCG_0092) 
protein is present only in tuberculosis complex mycobacteria 
and elicited DTH reactions in tuberculosis patients 
comparable to those elicited by tuberculin.15 The results 
suggest that this molecule can be an important tool for a 
more specific diagnosis of tuberculosis in non-BCG vaccinated 
individuals;15 however, it does not alleviate the problem with 
BCG vaccinated individuals. 
Production of recombinant BCG_0092 proved to be difficult.15 
Synthetic peptides containing the major T cell epitopes of 
this protein could overcome the problem. Moreover, a BCG 
deficient in BCG_0092 would allow the use of this antigen as 
a tool for the diagnosis of tuberculosis infection even in BCG 
vaccinated individuals. BCG vaccination could then be carried 
out in humans and animals, without interfering with this new 
diagnostic test. In this work we performed bioinformatics 
analyses with the BCG_0092 sequence in order to identify 
major T cell epitopes and knocked out the BCG_0092 gene 
from BCG by homologous recombination. The development 
of diagnostic tests which can differentiate vaccinated and 
tuberculosis-infected individuals could enhance the use of 
tuberculosis vaccines on a wider scale.
Material and methods
Sequence similarity search of BCG_0092 gene
To identify the presence of homologous genes, we did the 
BLASTP search and defined as homologous if (1) they had a 
FASTA E-score < e-10; (2) similarity was ≥ 50%; (3) the length of 
the alignable region between the two sequences was > 50% 
of the longer protein. This sequence was obtained directly 
from the National Center for Biotechnology Information (NCBI) 
using Nucleotide BLAST search. Settings were Mycobacterium 
Organism and PSI-BLAST Algorithm. Multiple alignments 
of each clusters were obtained by the program ClustalW2, 
followed by manual inspection and editing.16
Hydrophobicity 
The BCG_0092 amino acid sequence was analyzed using the 
hydrophobicity indices determined by HPLC described by 
Cowan & Whittaker17 using the Vector NTI Advance™11 
software to identify the hydrophobic regions presents in the 
protein.
MHC-I antigenic peptide prediction
The possible major histocompatibility complex I (MHC-I) 
immunogenic peptide epitopes for the antigen BCG_0092 
and the proteasome cleavage prediction were computed by 
the program MHC-I Antigenic Peptide Processing Prediction 
(MAPPP), which is available on the website (http://www.mpiib-
berlin.mpg.de/MAPPP/). A combination of cleavage algorithm 
to calculate the cleavages after a single residue was defined by 
FRAGPREDICT and PAProc with MHC binding matrices defined 
by SYFPEITHI and BIMAS in the expert mode of MAPPP were 
used.18 Parameters for FRAGPREDICT were set at 0.6 (minimal 
residue cleavage and fragment cleavage probability) and at 0.3 
in PAProc. We set all MHC-haplotypes and a range for length 
of peptide fragment of 8 to 10 amino acids. The threshold 
was set at an overall score of 0.9 expected for the gene 
product BCG_0092, for which we chose an overall score of 0.8. 
All peptides predicted were either 9- or- 10 mers. 
Bacterial strains and media
M. bovis BCG Pasteur strain 1173P2 was used as a source of 
DNA and as the parent strain for deletion of the dppd gene 
(GenBank accession number NC_008769, locus_tag BCG_0092) 
by homologous recombination. The strain was cultured in 
Middlebrook 7H9 (Difco) liquid medium supplemented with 
10% of oleic acid albumin/dextrose complex (OADC; Difco), 
0.05% Tween 80, and Middlebrook 7H11 (Difco) solid medium 
supplemented with 10% OADC. Recombinants were selected 
on 7H11 medium supplemented with 20 µg/mL kanamycin, 
100 µg/mL X-Gal and 10% of sucrose when necessary.
Knockout construction
Unmarked BCG ΔBCG_0092 was constructed as previously 
described.19 This strategy involves PCR amplifying 
chromosomal regions from either side of the gene of interest 
and cloning them into a suicide vector containing kanamycin 
resistance, lacZ and the counter selective sacB gene. When 
transformed into mycobacteria, the plasmid integrates into 
the chromosome by a single cross-over to give LacZ+, KanR 
colonies. Spontaneous double crossovers, which result in 
wild type revertants or knock-outs, can then be selected by 
using SacB. The homologous chromosomal regions were PCR 
amplified from regions upstream (0091F- CGA GAA GCT TGA 
AGT TAC CAT CGG CAA GA and 0091R- ACT AGG ATC CCC 
TTA ACG ACG AGC CGG T) and downstream (0093F- AAT AGG 
ATC CGC CGC GGC AAT GAG T 0093R- CAT CTT AAT TAA TTG 
AGC CTG GCG GCC ATT) of the BCG Pasteur. These were cloned 
into p2-NIL using HindIII/BamHI and BamHI/PacI restriction 
sites. The resulting plasmid was ligated to the pGOAL-19 
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Fig. 1 - Hydrophobicity of the amino acid sequence of 
BCG_0092. Above baseline are the highly hydrophobic 
regions and below baseline the regions with low 
hydrophobicity.
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PacI fragment20 generating the plasmid named pGOAL-
19/BCG_0091.0093. To transform the knockout plasmids 
into mycobacteria, cultures in logarithmic growth at OD600 
of 0.6-1 were harvested by centrifugation. The pellet was 
washed in ´1, ´0.5 and ´0.2 volumes of 10% glycerol (37°C for 
BCG) and the cells were then resuspended in ´0.01 volume. 
A 200 mL aliquot of competent cells were transformed by 
electroporation (25 mF, 1000 W, 2.5 V) with approximately 
1 µg UV irradiated (100 mJ/cm2) plasmid. BCG cells were 
recovered in 10 mL 7H9 for 12-24 h and plated on 7H11 
with kanamycin and X-Gal. Colonies with β-galactosidase 
activity were sub-cultured onto plates containing X-Gal 
and 10% sucrose. White colonies were selected and their 
genotype determined by PCR using 0091-F and 0093-R, and 
by Southern blot using probes containing the homologous 
regions, the BCG_0092 gene and pGOAL-19.
Results 
Sequence similarity search of BCG_0092 gene
The similarities between the M. tuberculosis BCG_0092 gene and 
their orthologues in other mycobacterial species, especially 
environmental mycobacteria, were analyzed using the 
ClustalW2.16 Clustal W2 analysis revealed the presence of 
BCG_0092 in four mycobacterial species (M. tuberculosis, M. bovis, 
M. marinum, M. ulcerans). The analysis showed that the identity 
of BCG_0092 gene among M. tuberculosis complex species 
(M. tuberculosis, M. bovis and M. bovis BCG) is 100%. Orthologues 
of the  gene are also present in M. marinum and M. ulcerans, two 
slow-growing cutaneous pathogens; however, the nucleotide 
sequence has an identity of only 79%. This shows that the use 
of BCG_0092 protein in a diagnostic test can result in a specific 
diagnosis of tuberculosis.
Hydrophobicity 
The BCG_0092 amino acid sequence was analyzed to identify 
the hydrophobic regions present in the protein using the 
hydrophobicity indices determined by HPLC described 
by Cowan & Whittaker17 using the Vector NTI Advance™ 
11software (Invitrogen). The first 77 amino acid contain highly 
hydrophobic residues (Fig. 1).
MHC-I antigenic peptide prediction
The cleavage probability of specific fragments from 
BCG_0092 protein was determined by MAPPP.21 For that 
the probability of a cut after each residue within the 
sequence and the cleavage probability for all possible 
fragments between two cut-sites and with the right length 
were calculated. The cleavage probability for a fragment 
depends on the probability of both the N- and the C-residue, 
as well as the probabilities of the residues between these 
sites. The flanking regions to the left and the right of a 
fragment are considered. Twenty-nine fragments from 
BCG_0092 were identified (data not shown). However, 17 
residues had the score above 0.9.
The prediction also was performed by MAPPP21 which 
combines existing prediction tools for proteasomal processing 
and MHC class I anchoring. The prediction of the peptides 
binding to MHC class I molecules is based on a score 
calculated for each subsequence. Each amino acid at a specific 
position within a subsequence is given a value. Depending on 
the algorithms selected in the form, the values for the 8 to 10 
amino acids are then multiplied (BIMAS) or added (SYFPEITHI) 
to determine the score for the subsequence. These values 
have been pre-calculated and stored in static matrices. The 
pre-calculation was done by algorithms and background data 
tables at BIMAS and SYFPEITHI22 matrices.
We considered the epitopes when the MHC bound epitope 
evolved from a proteasomal cleaved fragment with exactly 
the same size and when it was trimmed at the n-terminal 
side to get the epitope (with a mechanism already known to 
exist). Eight predicted antigenic peptides from BCG_0092 have 
the highest probability to be processed and finally presented 
on the cell surfaces. The alleles that have the possibility of 
binding to the peptides from BCG_0092 belonged to HLA-A 
(human leukocyte antigen) and HLA-B. 
Knockout construction
The sequences upstream and downstream of the target gene 
were cloned into a suicide vector. The plasmid containing the 
sequences that flank the BCG_0092 gene was named pGOAL-
19/BCG_0091.0093. Unmarked M. bovis BCG ΔBCG_0092 was 
successfully constructed by homologous recombination using 
the strategy described by Parish and Stoker.20 The knockout 
genotype was confirmed by PCR using primers that anneal to a 
sequence flanking the knockout target. The knockout genotype 
allowed amplification of a fragment of 1,822 bp, while the 
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Fig. 2 - Agarose gel electrophoresis of PCR products using 
primers flanking the BCG_0092 gene. Lane 1, 1 Kb DNA 
ladder (Invitrogen); lane 2, the BCG_0092 knockout mutant 
-BCG PasteurΔBCG_0092; lane 3, BCG WT (negative control); 
lane 4, pGOAL-19/BCG_0091.0093 (positive control).
wild BCG resulted in the amplification of a 2,248 bp fragment 
(Fig. 2). PCR using the BCG_0092 gene as target resulted in no 
amplification, further confirming the knockout genotype (data 
not shown). Southern blot probing with BCG_0092 gene and 
pGOAL-19 also confirmed the knockout genotype (data not 
shown).
Discussion
To perform a rational design of a new TB diagnostic strategy, 
bioinformatics analyses of BCG_0092 protein were carried out. 
We evaluated (1) the presence and relatedness of this protein 
among Mycobacterium spp.; (2) the hydrophobicity properties of 
the protein; and (3) the presence of predicted dominant MHC 
class I epitopes. 
The similarity analysis has been possible because 
there are presently 14 complete mycobacterial genome 
sequences deposited in GenBank, representing nine species: 
M. tuberculosis; M. bovis; M. avium; M. smegmatis; M. ulcerans; M. 
gilvum; M. leprae; M. vanbaalenii; M. marinum; M. abscessus.23-28 
Blast analysis with the BCG_0092 protein sequence revealed 
no match with M. tuberculosis H37Rv. When a careful analysis 
was carried out, an error in the annotation of the genome 
of several members of the M. tuberculosis complex was 
identified. The annotated coding sequence for this gene uses 
an alternative start codon, resulting in a distinct amino acid 
sequence for the Rv0061 (BCG_0092), the coding sequence for 
the DPPD protein.
In 2000, a study performed Southern blot analysis with 
DNA from a few species of mycobacteria and the DPPD gene 
(BCG_0092) was shown to be present in M. tuberculosis and 
in M. bovis BCG.14 At that time, only a few mycobacterial 
genomes had been sequenced. The in silico analysis that we 
carried out confirms the results obtained by Coler et al.14 
and adds information regarding the analysis of 14 other 
genome sequences. 
The identification of hydrophobic domains and prediction 
of binding of MHC I molecules to peptides is important to the 
development of rational design diagnosis. The hydrophobic 
interactions are the most important non-covalent forces that 
are responsible for different phenomena such as structure 
stabilization of proteins,18 binding of enzymes to substrates,29 
and folding of proteins.30 In a previous work, Coler et al.14 
tested several alternatives for expression of BCG_0092 (named 
DPPD by the authors). However, none of these systems 
provided reasonable expression of this protein. To overcome 
this problem, the DPPD was expressed as a chimeric construct 
with a 14-kDa C-terminal fragment of the M. tuberculosis 
protein named Ra12.14
The prediction of binding of MHC I molecule to a peptide 
shows the ability of binding of MHC molecules, which 
will transport the peptide to the cell surface.31 In an 
infection with M. tuberculosis the protein BCG_0092, have 
cleavage probability in specific fragment, some of these 
residues have the possibility of binding to MHC I molecules 
and as a consequence the generation of BCG_0092 specific 
immune response.
Based on the hydrophobici ty  analysis  and the 
identification of predicted MHC epitopes, we suggest 
the cloning and expression of the C-terminal region of the 
BCG_0092 protein (from 77 amino acid to 141 amino acid). In 
this hydrophilic region five epitopes with ability of binding 
to MHC molecules were identified. The DPPD (corresponding to 
BCG_0092) protein was the only antigen that elicited 
DTH reactions in tuberculosis patients comparable 
to those elicited by tuberculin.15 The results suggest that 
this molecule has the potential for the developing of 
more specific diagnostic tests for tuberculosis in non-BCG 
vaccinated individuals. An alternative is to use these five 
epitopes present in this region or the three present in the 
hydrophobic region, synthetically produced, in a cocktail of 
epitopes.32
Synthetic peptides representing fragments of ESAT-
6, MPB64, MPB83, MPB70, and CFP-10 alone or in different 
combinations, have been described recently as useful in the 
detection of TB in cattle or humans,12,19,33,34 in some cases 
with limited success.
A diagnostic test using peptides derived from BCG_0092 
individually or as a cocktail, could improve the specificity and 
sensitivity of such test. This test could be based on the DTH 
reaction similar to the tuberculin test, or a test based on the 
detection of IFNγ production when PBMC (peripheral blood 
mononuclear cell) are sensitized with the BCG_0092-derived 
MHC epitopes. 
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Fig. 3 - Alignment of the M. bovis genome at the locus 
(BCG_0092) with the DNA construct used for BCG_0092 
knockout by homologous recombination.
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The BCG_0092 gene is expressed in M. bovis BCG. A 
diagnostic test using peptides derived from this antigen 
would react with vaccinated individuals, decreasing the 
specificity of the test. To allow the vaccination with BCG 
without interfering in the diagnostic test proposed in this 
work, we used a strategy for knocking out the BCG_0092 open 
reading frame (Fig. 3).
The encouraging results obtained with use of DPPD 
(BCG_0092) in the skin test, with similar results to PPD in 
terms of sensitivity and with improved specificity15 prompted 
us to investigate the possibility of genetically modifying 
the BCG strain in order to knock out this antigen. This BCG 
Δbcg_0092 strain will be evaluated in animal models of 
tuberculosis to ascertain that the protective properties 
of the BCG vaccine have not been compromised. It is expected 
that this mutant strain will be able to protect against the 
severe forms of tuberculosis without sensitizing the animal 
against the BCG_0092 antigen. If this hypothesis is confirmed, 
a new perspective for vaccination of farm animals with BCG 
will be established. This will provide not only protection 
against tuberculosis but also the possibility of using BCG as 
a multivalent vaccine vector.2
The results demonstrated that dominant MHC epitopes 
of carefully selected mycobacteria complex-specific 
protein can be used to devise a simple peptide-based 
immunodiagnostic test. Moreover, the knockout BCG 
strain could allow differentiation between vaccinated and 
infected individuals. These findings support the systematic 
application of bioinformatics tools in combination with 
in vitro methods for the rational design of diagnostic and 
vaccination strategies for TB. 
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